We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+57.73%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$2.27B
AUM Growth
+$886M
Cap. Flow
+$626M
Cap. Flow %
27.61%
Top 10 Hldgs %
43.12%
Holding
273
New
99
Increased
46
Reduced
48
Closed
43

Top Buys

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$15.3M
2
ASND icon
Ascendis Pharma A/S
ASND
+$14.4M
3
PRTA icon
Prothena Corp
PRTA
+$14M
4
BMY icon
Bristol-Myers Squibb
BMY
+$11.6M
5
PCVX icon
Vaxcyte
PCVX
+$9.67M

Top Sells

Rank Stock Value
1
OCUL icon
Ocular Therapeutix
OCUL
+$15.3M
2
ETNB
89bio
ETNB
+$7.86M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$7.57M
4
RPTX
Repare Therapeutics
RPTX
+$5.86M
5
ATRA icon
Atara Biotherapeutics
ATRA
+$5.53M

Sector Composition

Rank Sector Weight
1 Healthcare 23.89%
2 Industrials 0.04%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KURA icon
201
Kura Oncology
KURA
$800M
$366K 0.02%
11,203
+5,000
+81% +$176K
QNCX icon
202
Quince Therapeutics
QNCX
$22.9M
$361K 0.02%
65
-135
-68% -$1.2M
ARVN icon
203
Arvinas
ARVN
$518M
$358K 0.02%
+4,216
New +$145K
RAPT
204
PUT
DELISTED
RAPT Therapeutics
RAPT
$309K 0.01%
1,950
– –
BLU
205
DELISTED
BELLUS Health Inc.
BLU
$306K 0.01%
100,000
– –
NVAX icon
206
Novavax
NVAX
$1.2B
$294K 0.01%
2,636
– –
TPST icon
207
Tempest Therapeutics
TPST
$13.7M
$289K 0.01%
693
– –
PRAX icon
208
Praxis Precision Medicines
PRAX
$8.58B
$275K 0.01%
+333
New +$194K
INBX
209
DELISTED
Inhibrx, Inc. Common Stock
INBX
$266K 0.01%
+8,076
New +$215K
SLNO
210
DELISTED
Soleno Therapeutics
SLNO
$236K 0.01%
+8,164
New +$236K
IVA
211
Inventiva
IVA
$1.06B
$214K 0.01%
15,000
– –
CRBP icon
212
Corbus Pharmaceuticals
CRBP
$166M
$174K 0.01%
+4,637
New +$173K
EYPT icon
213
CALL
EyePoint Inc
EYPT
$1.03B
$119K 0.01%
+17,900
New +$83.7K
BXRX
214
DELISTED
Baudax Bio, Inc. Common Stock
BXRX
$101K ﹤0.01%
71
– –
GBT
215
PUT
DELISTED
Global Blood Therapeutics, Inc.
GBT
$91K ﹤0.01%
2,100
– –
KNTE
216
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$79K ﹤0.01%
+2,000
New +$80.3K
RCKT icon
217
Rocket Pharmaceuticals
RCKT
$340M
$75K ﹤0.01%
+1,400
New +$51K
ZYME icon
218
Zymeworks
ZYME
$1.61B
$73K ﹤0.01%
+1,556
New +$72.3K
RAPT
219
CALL
DELISTED
RAPT Therapeutics
RAPT
$69K ﹤0.01%
438
-225
-34% -$48.9K
TBIO
220
PUT
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$67K ﹤0.01%
+3,600
New +$64.4K
ALPN
221
DELISTED
Alpine Immune Sciences Inc
ALPN
$60K ﹤0.01%
4,739
– –
MITO
222
DELISTED
Stealth BioTherapeutics Corp. ADS
MITO
$57K ﹤0.01%
37,597
– –
IGMS
223
DELISTED
IGM Biosciences
IGMS
$27K ﹤0.01%
+300
New +$21.1K
APTO
224
DELISTED
Aptose Biosciences, Inc.
APTO
$18K ﹤0.01%
9
– –
BLUE
225
DELISTED
bluebird bio
BLUE
$12K ﹤0.01%
22
-3,088
-99% -$1.96M
7 8
9
10 11

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2020 Portfolio in Review

As of Q4 2020, Ikarian Capital held 273 positions worth $2.27B, up 64% from $1.38B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Ikarian Capital deployed $626M of net new capital in Q4 2020, opening 99 new positions and adding to 46 existing holdings. Its largest new stake was Morphic Holding, Inc. Common Stock: 516,763 shares worth $17.3M.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 25% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was Ocular Therapeutix, an estimated $15.3M trimmed.

  • Ikarian Capital's largest Q4 2020 buy was Morphic Holding, Inc. Common Stock: 516,763 shares worth $17.3M.
  • Ikarian Capital added most to Bristol-Myers Squibb in Q4 2020, an estimated $11.6M increase.
  • Ikarian Capital's biggest Q4 2020 reduction was Ocular Therapeutix, cutting an estimated $15.3M.
  • Ikarian Capital fully exited Repare Therapeutics in Q4 2020, selling an estimated $5.86M.
  • Ikarian Capital's ten largest holdings make up 43% of its $2.27B portfolio in Q4 2020.
  • Ikarian Capital opened 99 new positions and closed 43 in Q4 2020.
  • Ikarian Capital's portfolio value rose 64% quarter-over-quarter to $2.27B.

Based on Ikarian Capital's 13F filing for Q4 2020, filed 12 Feb 2021.